Member Info for Laura2022

It has been confirmed today

I have taken a small position before the 23rd June cut off date,interesting developments too on other assets mentioned in today's RNS

Would be good for VAL/PYC

Dr Suzanne Dilly, CEO of ValiRx commented, "Global exclusivity was initially awarded to TheoremRx to enable the progression of their financing, which on completion will enable execution of the sub-license of VAL201 to TheoremRx.  We remain fully supportive of the TheoremRx team and continue to closely monitor their progress. However, this modification to the agreement allows ValiRx to explore additional partners in a defined geographic region while TheoremRx continue their process. Recent evidence suggests that China is increasing investment in innovative pharmaceutical development and may offer additional routes for commercialisation

Dr Suzanne Dilly, CEO of ValiRx commented, "Global exclusivity was initially awarded to TheoremRx to enable the progression of their financing, which on completion will enable execution of the sub-license of VAL201 to TheoremRx.  We remain fully supportive of the TheoremRx team and continue to closely monitor their progress. However, this modification to the agreement allows ValiRx to explore additional partners in a defined geographic region while TheoremRx continue their process. Recent evidence suggests that China is increasing investment in innovative pharmaceutical development and may offer additional routes for commercialisation

Nice to see some further buys recently

 Letter of Intent with TheoremRx for VAL201 continues to be exclusive at this time as we still expect their funding efforts will progress to a conclusion

Things could heat up,glad I purchased some last week

Thanks for the links

Breast cancer drug cuts risk of most common form returning by 25%

Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly

Andrew Gregory Health editor in Chicago

@andrewgregory

Fri 2 Jun 2023 13.00 BST

Thousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.

More than 2 million people globally are diagnosed each year with the disease, which is the world’s most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.

Now, “very promising” research presented at the American Society of Clinical Oncology (Asco) annual meeting, the world’s largest cancer conference, suggests a new targeted therapy drug, ribociclib, could be gamechanging. Trial results show it can boost survival and significantly slash the chances of cancer coming back.

Ribociclib has previously shown survival benefits in breast cancer patients whose disease has spread. But in the new study, researchers discovered it may also boost outcomes for patients with much earlier-stage disease, including those with cancer that has not yet spread to the lymph nodes.

The findings excited researchers and oncologists at Asco’s annual meeting in Chicago because the data suggests the drug, also known as Kisqali, could ward off the threat of cancer returning in a broad population, and change global practice.

Ribociclib is a targeted therapy called a small molecule inhibitor. It works by targeting proteins in breast cancer cells called CDK4 and CDK6, which modulate cell growth, including the growth of cancer cells.

Does SAB mean science advisory board ?,this is his profile on PYC website

Mark Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology and consultant Medical Oncologist at the Oxford Cancer and Haematology Centre.Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research UK Oxford Centre. 

Mark Middleton mentioned in the BBC article

 than 350 of those in the study - the biggest of its kind in patients with suspected cancer symptoms - were subsequently diagnosed with cancer, using traditional methods such as scans and biopsies. About:

75% of those testing positive on the blood test were found to have cancer2.5% of those testing negative were found to have cancer

Although not accurate enough to "rule in or rule out cancer", the test was really useful for patients lead researcher Prof Mark Middleton told BBC News.

"The test was 85% accurate in detecting the source of the cancer - and that can be really helpful because so many times it is not immediately obvious when you have got the patient in front of you what test is needed to see whether their symptoms are down to cancer," he said.

"With that prediction from the test, we can decide whether to order a scope or a scan and make sure we are giving the right test the first time."

The findings will be presented at the American Society of Clinical Oncology conference, in Chicago, and published in The Lancet Oncology journal.

Good morning Kidlington

What is a SAB please ?

Https://www.bbc.co.uk/news/health-65775159

Perhaps save your energy for AMC CPX and your other investments

Not quite sure why you continue to post here

I have taken a small amount now the funding has been formalised

Thankyou N and L and Kidlington

I corrected my earlier mistake

The project is expected to be concluded over the next two months, and a longer-term collaboration is currently under discussion.

 

Physiomics CEO, Dr Jim Millen commented:

"We are delighted to have been selected by The University of Sheffield to support this highly innovative research program with our analytical and modelling capabilities. We look forward to working with Dr Campbell and her colleagues and believe that both our analytical capabilities, as well as our contacts and experience within the pharmaceutical industry, could add real value to the initiative."

 

However, on the topic of grant funding,this was from the April update

We see significant potential in the adaptation of our current personalised dosing tool to support clinical decision making on the use of this expensive biological drug and indeed the concept has received early positive feedback when tested with a small number of US clinicians. The Company is actively exploring non-dilutional grant funding opportunities for all its personalised dosing initiatives and if successful these could provide additional sources of funding in FY24

Apologies,I was meaning that for another company

Just reading this Rns now...looks interesting

Great news

This is equivalent to over 12mths funding too ,extends cash runway till 2025

Good points from you

Particularly this one from Kidlington

"

The potential value is to become a packaged software licensor which is higher gross margin, repeatable and leveragable model. We await evidence of that but the signs are good because you don't get to collaborate with likes of Bicycle/Merck if you don't have good/unique insights/IP... DoseMeRx type collabs are key thing to watch.

Then once it is 'software' there is potential for ML/AI uses..

The potential valuation spectrum on successful transformation/execution goes from

Consulting 0-10p

Software 10-100p

AI/ML 100p+"

This was re iterated in the Q and A which I assume you have not seen nor read

Rather than plague the discussion boards of VAL and PYC maybe spend time on investments you have (if any ?)